105 related articles for article (PubMed ID: 28643458)
21. Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL).
Won YW; Kwon JH; Lee SI; Oh SY; Kim WS; Kim SJ; Won JH; Kim KH; Park SK; Kim JS; Suh C; Yoon DH; Park JS; Kim MK; Kim H; Kang HJ; Mun YC; Kwak JY; Kim HJ; Eom HS
Ann Hematol; 2012 Feb; 91(2):223-33. PubMed ID: 21789622
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.
Vassilakopoulos TP; Dimopoulou MN; Angelopoulou MK; Petevi K; Pangalis GA; Moschogiannis M; Dimou M; Boutsikas G; Kanellopoulos A; Gainaru G; Plata E; Flevari P; Koutsi K; Papageorgiou L; Telonis V; Tsaftaridis P; Sachanas S; Yiakoumis X; Tsirkinidis P; Viniou NA; Siakantaris MP; Variami E; Kyrtsonis MC; Meletis J; Panayiotidis P; Konstantopoulos K
Oncologist; 2016 Mar; 21(3):343-53. PubMed ID: 26921291
[TBL] [Abstract][Full Text] [Related]
23. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
24. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
25. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
[TBL] [Abstract][Full Text] [Related]
27. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
[TBL] [Abstract][Full Text] [Related]
28. Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia.
Shafi RG; Al-Mansour MM; Kanfar SS; Al Hashmi H; Alsaeed A; Al-Foheidi M; Ibrahim EM
Oncol Res Treat; 2017; 40(5):288-292. PubMed ID: 28380488
[TBL] [Abstract][Full Text] [Related]
29. Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.
Klimm B; Franklin J; Stein H; Eichenauer DA; Haverkamp H; Diehl V; Fuchs M; Borchmann P; Engert A
J Clin Oncol; 2011 Oct; 29(29):3914-20. PubMed ID: 21911729
[TBL] [Abstract][Full Text] [Related]
30. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
[TBL] [Abstract][Full Text] [Related]
31. Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.
Samant R; Alomary I; Alsaeed E; Al-Jasir B; Bence-Bruckler I; Cross P; Genest P; Huebsch L
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1166-70. PubMed ID: 19695788
[TBL] [Abstract][Full Text] [Related]
32. Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.
Almagro-Casado E; Sánchez A; Cantos B; Salas C; Pérez-Callejo D; Provencio M
Clin Transl Oncol; 2016 Jan; 18(1):99-106. PubMed ID: 26530956
[TBL] [Abstract][Full Text] [Related]
33. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
34. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.
Besson C; Lancar R; Prevot S; Brice P; Meyohas MC; Marchou B; Gabarre J; Bonnet F; Goujard C; Lambotte O; Boué F; Mounier N; Partisani M; Raffi F; Costello R; Hendel-Chavez H; Algarte-Genin M; Trabelsi S; Marchand L; Raphael M; Taoufik Y; Costagliola D
Clin Infect Dis; 2015 Nov; 61(9):1469-75. PubMed ID: 26223997
[TBL] [Abstract][Full Text] [Related]
35. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Eroglu C; Kaynar L; Orhan O; Keklik M; Sahin C; Yildiz OG; Mentes S; Kurnaz F; Aslan D; Sivgin S; Soyuer S; Eser B; Cetin M; Unal A
Am J Clin Oncol; 2015 Feb; 38(1):68-73. PubMed ID: 23563207
[TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin PJ; Lowry L; Horwich A; Jack A; Mead B; Hancock BW; Smith P; Qian W; Patrick P; Popova B; Pettitt A; Cunningham D; Pettengell R; Sweetenham J; Linch D; Johnson PW
J Clin Oncol; 2009 Nov; 27(32):5390-6. PubMed ID: 19738111
[TBL] [Abstract][Full Text] [Related]
37. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
Gallamini A; Hutchings M; Rigacci L; Specht L; Merli F; Hansen M; Patti C; Loft A; Di Raimondo F; D'Amore F; Biggi A; Vitolo U; Stelitano C; Sancetta R; Trentin L; Luminari S; Iannitto E; Viviani S; Pierri I; Levis A
J Clin Oncol; 2007 Aug; 25(24):3746-52. PubMed ID: 17646666
[TBL] [Abstract][Full Text] [Related]
38. Impact of the Epstein-Barr virus positivity on Hodgkin's lymphoma in a large cohort from a single institute in Korea.
Koh YW; Yoon DH; Suh C; Huh J
Ann Hematol; 2012 Sep; 91(9):1403-12. PubMed ID: 22526365
[TBL] [Abstract][Full Text] [Related]
39. Radiation therapy overcomes adverse prognostic role of cyclooxygenase-2 expression on Reed-Sternberg cells in early Hodgkin lymphoma.
Mestre F; Gutiérrez A; Rodriguez J; Ramos R; Garcia JF; Martinez-Serra J; Casasus M; Nicolau C; Bento L; Herraez I; Lopez-Perezagua P; Daumal J; Besalduch J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):84-90. PubMed ID: 25475251
[TBL] [Abstract][Full Text] [Related]
40. Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma.
Maraldo MV; Aznar MC; Vogelius IR; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1057-65. PubMed ID: 23200817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]